1) Massachusetts owns the orphan drug market. Here’s the proof. – BBJ, 11/9/2015
Bay State companies have more of the biggest drugs for rare diseases either already approved or in late-stage development than any other state in the nation.
2) IBM Watson to help pinpoint rare diseases at Boston Children’s Hospital – BBJ, 11/4/2015
A computer that can help pinpoint a rare disease might sound like a development out of Star Wars. But that’s the hope of a new collaboration between Boston Children’s Hospital and supercomputer IBM Watson, which has a health division based out of Cambridge.
3) Lexington firm’s new sepsis test places it among life sciences giants – BBJ, 11/12/2015
T2 Biosystems (Nasdaq: TTOO) beat much larger companies like Boston Scientific (NYSE: BSX) and Medtronic (NYSE: MDT) to take the top spot in the award competition’s Best Medical Technology category. The
4) Cambridge biotech led by former GSK exec slips onto Nasdaq with $102M IPO – BBJ, 11/13/2015
Wave (Nasdaq: WVE), a biotech with corporate offices in Alewife but based in Singapore, managed to raise $102 million on Wednesday, the same day that Voyager (Nasdaq: VYGR) was raising $70 million. The company quietly filed its plans to go pubic with the SEC last month, taking advantage of the 2012 JOBS Act which allows companies to go public with fewer regulatory filings required.
5) Symposium highlights CROs and CMOs, the unsung heroes of biotech – BBJ, 11/11/2015
This week, the state’s biotechnology lobbying group, MassBio, will showcase what could be considered the unsung heroes of the local industry hub: the labs that can be hired to oversee research into or manufacturing of new drugs. And while the area’s so-called contract research organizations and contract manufacturing organizations may not attract the attention of our biotech firms, their innovations are no less important to create better ways that drugs can help patients.